1,625 results on '"Oertel, Wolfgang H."'
Search Results
2. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction
3. Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy
4. Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern—case reports
5. Occipital hypometabolism is a risk factor for conversion to Parkinson’s disease in isolated REM sleep behaviour disorder
6. The functional brain connectome in isolated rapid eye movement sleep behavior disorder and Parkinson’s disease
7. Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
8. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
9. Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy
10. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
11. FDG-PET combined with learning vector quantization allows classification of neurodegenerative diseases and reveals the trajectory of idiopathic REM sleep behavior disorder
12. Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease
13. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder
14. Increased muscle sympathetic nerve activity and impaired baroreflex control in isolated REM-sleep behavior disorder
15. microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers
16. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
17. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.
18. RBD, Gastric Peptides, and Gastric Motility
19. Brain Imaging in RBD
20. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.
21. α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
22. Reduced Gastric Contraction in Rapid‐Eye‐Movement Sleep Behavior Disorder and De Novo Parkinson's Disease
23. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease
24. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial
25. A punch in the gut – Intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease
26. Transdermal Nicotine Treatment and Progression of Early Parkinson’s Disease
27. Progressive Supranuclear Palsy
28. The spectrum of “off” in Parkinson's disease: What have we learned over 40 years?
29. Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease
30. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons
31. Reduced Gastric Contraction in Rapid‐Eye‐Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
32. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease.
33. Evaluation of a Structured Screening Assessment to Detect Isolated Rapid Eye Movement Sleep Behavior Disorder
34. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, 4-repeat/full-length tau and alpha-synuclein
35. Dermal Real‐Time Quaking‐Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early α‐Synucleinopathy
36. Drug Safety Analysis in a Real-Life Cohort of Parkinson’s Disease Patients with Polypharmacy
37. Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder
38. Biceps electromyography in dialeptic and automotor seizures with and without secondary generalization
39. Ghrelin and Parkinson’s Disease
40. Brain Imaging in RBD
41. RBD, Gastric Peptides, and Gastric Motility
42. Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse
43. Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study.
44. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease
45. Is increased spinal nociception another hallmark for Parkinson’s disease?
46. Evaluation of a structured screening assessment to detect patients with isolated REM Sleep Behavior Disorder
47. Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity
48. Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice
49. Immunization as Treatment for Parkinson’s Disease
50. Neurogenesis in Substantia Nigra of Parkinsonian Brains?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.